Monday , May 17 2021

They successfully tested Zika vaccine in mice



A team of Spanish researchers have successfully tested a new vaccine in mice capable, at one dose, of controlling Zika virus infection.

AFP PHOTO / Raul Arboleda

A team of Spanish researchers have successfully tested a new vaccine in mice capable, at one dose, of controlling Zika virus infection.

The results of its development have been published in the journal Scientific Reports, in an article signed between Juan García-Arriaza and Mariano Esteban of the National Center for Biotechnology, the CSIC Center and Miguel Angel Martin-Acesby from the National Institute of Agricultural and Food Research and Technology.

The new vaccine, called MVA-ZIKV, was designed using the same strategy previously used by disease vaccine authors such as Ebola, chikungunya fever, hepatitis C, and HIV – the latter's last clinical trial began, and the rest were tested in animals.

Thus, scientists selected the key genes in Zika's disease to activate the immune response and introduced them through genetic engineering into DNA to another virus that acts as a vector to reach the cells of the body.

In particular, the researchers relied on the prM and E genes, the most important Zika viruses for activating immune responses in the body that enable the activation of T and B lymphocytes, key cells in defense against pathogens.

When these lymphocytes are activated, antibodies that neutralize the virus are produced and are called cells T CD8 They destroy the infected cells, Efe Mariano Esteban explains, adding that this achieves a greater degree of protection.

"We have shown that immunization of mice with MVA-ZIKV stimulates the immune response against the Zika virus with specific activation of CD8 T cells, as well as high levels of antibodies capable of neutralizing the virus," said the scientist.

According to this new work, one dose of the MVA-ZIKV vaccine is able to control the infection of Zika virus in mice, effectively protecting against infection from the virus.

Promising results

Although there are already other vaccine candidates, so far no one has been licensed, according to the CSIC, which suggests that "the promising results of this work strengthen the possibility that MVA-ZIKV can be considered a fight against Zika."

The next step, Esteban says, is to determine if the transfer of the mother-to-child virus can be prevented and the vaccine can be taken under clinical conditions, "for which economic support is needed."

"The vaccine has immunogenic and safety properties that make it suitable for a vaccine to prevent the disease and its spread," Garcia-Arriaza concludes. EFEfuturo


Source link